

Comment

Supplementary information to:

COVID vaccination logistics: five steps to take now

A Comment published in *Nature* 587, 194–196 (2020)

<https://doi.org/10.1038/d41586-020-03134-2>

Yot Teerawattananon & Saudamini Vishwanath Dabak

Supplementary Information: Additional Information and Acknowledgements (Date: 4 Nov 2020)

COVID vaccination logistics: five steps to take now

**Beyond vaccine safety, efficacy and procurement lie licensing and delivery — nations must get ready.
By Yot Teerawattananon^{1,2} and Saudamini Vishwanath Dabak^{1*}.**

1 The Health Intervention and Technology Assessment Program (HITAP), Thailand

2 Saw Swee Hock School of Public Health (SSHSPH), National University of Singapore (NUS).

*Corresponding author

saudamini.d@hitap.net

Phone: +662-590-4549

Additional information and acknowledgements

Dr. Yot Teerawattananon is involved in responding to the COVID-19 pandemic in the following positions: Member of the Review Committee for the COVID-19 Stimulus and Relief Packages of the Royal Thai government; Member of the Thai Ministry of Public Health (MoPH) Intelligence Unit for Policy Responses on COVID-19 Pandemic; and Member of the WHO's Working Group to develop the WHO Target Product Profiles for COVID-19 Vaccines.

The Health Intervention and Technology Assessment Program (HITAP) is funded by the Thailand Research Fund (TRF) under a grant for a Senior Research Scholar (RTA5980011). HITAP is supported by the International Decision Support Initiative (iDSI) to provide technical assistance on health intervention and technology assessment to governments in low- and middle-income countries. iDSI is funded by the Bill & Melinda Gates Foundation (OPP1202541), the UK's Department for International Development, and the Rockefeller Foundation. HITAP is also supported by the Access and Delivery Partnership (ADP), which is hosted by the United Nations Development Programme (UNDP) and funded by the Government of Japan.

HITAP received support from the following on COVID-19 projects: iDSI and the Ministry of Higher Education, Science, Research and Innovation, Royal Thai Government on the COVID-19 Multi-model Comparison Collaboration (CMCC), an initiative to provide guidance on the use of COVID-19 models in policymaking, carried out in collaboration with other partners; ADP, to host a series of webinars to share knowledge on the use of evidence to address healthcare challenges, including the COVID-19 pandemic; Health Systems Research Institute (HSRI) and the World Health Organization (WHO), to conduct an early Health Technology Assessment (HTA) of COVID-19 vaccines; the National Research Council of Thailand (NRCT) and the National Health Commission Office (NHCO), Thailand, to conduct a study on rationing scarce critical care resources during the COVID-19 pandemic in Thailand. The findings, interpretations and conclusions expressed in this article do not necessarily reflect the views of the funding agencies.

We thank Prof. Prabhat Jha from the Centre for Global Health Research, Unity Health Toronto and University of Toronto; Dr. Sonalini Khetrpal and Dai-Ling Chen from the Asian Development Bank (ADB); Dr. Jesse Bump from the Harvard T.H. Chan School of Public Health; Prof. Alec Morton from the University of Strathclyde; Dr. Suwit Wibulpolprasert and Dr. Supakit Sirilak from the Thai Ministry of Public Health; Dr. Wanrudee Isaranuwachai from HITAP; and Prof. Teo Yik Ying from the Saw Swee Hock School of Public Health for discussions on the topic. We are grateful to Christopher Painter from HITAP for providing comments on the paper and to Ms. Nicola Jones for her editorial support.